Abstract
Cannabis consumption has radically changed over the last several decades. Tetrahydrcannbidiol concentrations are rising, cannabidiol concentrations falling and cannabis is becoming legalized in several regions of the globe. Concerns have been raised as to the impact of increased cannabis exposure within the general population on public health. One of the more serious concerns is the potential relationship between cannabis consumption and psychosis. Research has shown a relationship between increasing cannabis use and increasing psychosis risk. This risk is moderated by other factors such as stress and a family history of psychosis. Within this context, it is important to determine potential markers for future psychosis risk. Genetic and epigenetic research in cannabis and psychosis is in its early stages. One common denominator between cannabis use disorder and psychosis is dopamine dysfunction. Research has begun to link heightened dopamine reactivity with the psychotomimetic effects of cannabis. Studies in COMT and DRD2 polymorphisms have failed to show greater associations with transition to psychosis. Studies of AKT1 have shown slightly more promising results. Genome-wide association studies have recently been published some indicating novel polymorphisms. These may pave the way to alternate hypotheses to explain the missing links between cannabis use and increased risk of psychosis. Such knowledge may eventually lead to new pharmacotherapies in addition to the means of screening patients for psychosis risk.
Keywords: Cannabis use disorder, psychosis, COMT, CNR1, GWAS.
Current Pharmaceutical Design
Title:Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond
Volume: 22 Issue: 42
Author(s): Amine Benyamina, Laurent Karila, Geneviève Lafaye and Lisa Blecha
Affiliation:
Keywords: Cannabis use disorder, psychosis, COMT, CNR1, GWAS.
Abstract: Cannabis consumption has radically changed over the last several decades. Tetrahydrcannbidiol concentrations are rising, cannabidiol concentrations falling and cannabis is becoming legalized in several regions of the globe. Concerns have been raised as to the impact of increased cannabis exposure within the general population on public health. One of the more serious concerns is the potential relationship between cannabis consumption and psychosis. Research has shown a relationship between increasing cannabis use and increasing psychosis risk. This risk is moderated by other factors such as stress and a family history of psychosis. Within this context, it is important to determine potential markers for future psychosis risk. Genetic and epigenetic research in cannabis and psychosis is in its early stages. One common denominator between cannabis use disorder and psychosis is dopamine dysfunction. Research has begun to link heightened dopamine reactivity with the psychotomimetic effects of cannabis. Studies in COMT and DRD2 polymorphisms have failed to show greater associations with transition to psychosis. Studies of AKT1 have shown slightly more promising results. Genome-wide association studies have recently been published some indicating novel polymorphisms. These may pave the way to alternate hypotheses to explain the missing links between cannabis use and increased risk of psychosis. Such knowledge may eventually lead to new pharmacotherapies in addition to the means of screening patients for psychosis risk.
Export Options
About this article
Cite this article as:
Benyamina Amine, Karila Laurent, Lafaye Geneviève and Blecha Lisa, Genetic Influences in Cannabis Use Disorder and Psychosis: Dopamine and Beyond, Current Pharmaceutical Design 2016; 22 (42) . https://dx.doi.org/10.2174/1381612822666160831095707
DOI https://dx.doi.org/10.2174/1381612822666160831095707 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Prolyl Endopeptidase in Intracellular Transport and Protein Secretion
CNS & Neurological Disorders - Drug Targets Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology Immunoregulatory Impact of Food Antioxidants
Current Pharmaceutical Design Omega-3 Fatty Acids and Hippocampal Neurogenesis in Depression
CNS & Neurological Disorders - Drug Targets Biological Active Peptides from Marine Sources Related to Gut Hormones
Current Protein & Peptide Science Consumption of Polyphenol Plants May Slow Aging and Associated Diseases
Current Pharmaceutical Design Targeting Hsp90 in Non-Cancerous Maladies
Current Topics in Medicinal Chemistry How to Get from Here to There: Macrophage Recruitment in Alzheimers Disease
Current Alzheimer Research The Role of Renin Angiotensin System Blockade in the Treatment of Atrial Fibrillation
Current Drug Targets - Cardiovascular & Hematological Disorders Hotspot Mutations in DICER1 Causing GLOW Syndrome-Associated Macrocephaly <i>via</i> Modulation of Specific microRNA Populations Result in the Activation of PI3K/ATK/mTOR Signaling
MicroRNA Radioligands for the PET Imaging of Metabotropic Glutamate Receptor Subtype 5 (mGluR5)
Current Topics in Medicinal Chemistry Opportunities for Nano-Formulations in Type 2 Diabetes Mellitus Treatments
Current Pharmaceutical Biotechnology Treating Depression in Coronary Artery Disease and Chronic Heart Failure: What’s new in using Selective Serotonin Re-Uptake Inhibitors?
Cardiovascular & Hematological Agents in Medicinal Chemistry Usefulness of 5 Minutes <sup>123</sup>I-mIBG Scan in Parkinson’s Disease and Heart Failure
Current Radiopharmaceuticals P-Glycoprotein and Breast Cancer Resistance Protein Affect Disposition of Tandutinib, A Tyrosine Kinase Inhibitor
Drug Metabolism Letters Gyroxin and Its Biological Activity: Effects on CNS Basement Membranes and Endothelium and Protease-Activated Receptors
Current Medicinal Chemistry One-Pot Green Synthesis of Some Novel N-Substituted 5-Amino-1,3,4- Thiadiazole Derivatives
Letters in Organic Chemistry Transcription Factor Co-expression Networks of Adipose RNA-Seq Data Reveal Regulatory Mechanisms of Obesity
Current Genomics Exploring the Multifunctional Neuroprotective Promise of Rasagiline Derivatives for Multi-Dysfunctional Alzheimer’s Disease
Current Pharmaceutical Design Positive Social Interactions in a Lifespan Perspective with a Focus on Opioidergic and Oxytocinergic Systems: Implications for Neuroprotection
Current Neuropharmacology